Seagen Inc (SGEN)

Etorro trading 970x250
Seagen Inc (SGEN) Logo

About Seagen Inc

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. Address: 21823 30th Drive SE, Bothell, WA, United States, 98021

Seagen Inc News and around…

Latest news about Seagen Inc (SGEN) common stock and company :

Investing $100,000 Into These 2 Stocks 10 Years Ago Would Have Made You a Millionaire Today
22 Nov, 2021 FinancialContent

And doing so wouldn't have involved gambling with your portfolio, either.

Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium
19 Nov, 2021 FinancialContent

Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium

Why Affirmed Stock Was Up More Than 12% Wednesday
17 Nov, 2021 FinancialContent

Positive trial results regarding the company's pipeline are buoying the stock's price.

Notable Seagen Insider Trades $1.2M In Company Stock
15 Nov, 2021 Yahoo! Finance

Vaughn B Himes, Insider at Seagen (NASDAQ:SGEN), made a large buy and sell of company shares on November 11, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Vaughn B Himes exercised options to purchase 6,000 Seagen shares at a price of $26.10 per share for a total of $156,600 on November 11. They then sold their shares on the same day in the open market. They sold at prices ranging from $177.94 to $179.84 to raise a total

Where Seagen Stands With Analysts
09 Nov, 2021 FinancialContent

Over the past 3 months, 6 analysts have published their opinion on Seagen (NASDAQ:SGEN) stock. These analysts are typically employed by ...

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
09 Nov, 2021 FinancialContent

Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE:NEWR) from Underweight to Overweight. For the ...

Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting
09 Nov, 2021 FinancialContent

Seagen Inc. (Nasdaq:SGEN), today announced the presentation of two new vedotin-based antibody-drug conjugate (ADC) programs at the Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting, taking place in Washington, D.C. and virtually, November 10-14, 2021. Each program combines antibodies targeted to an immune checkpoint [PD-(L)1 or B7-H4] with the cytotoxic properties of the vedotin payload. Preclinical data demonstrate promising antitumor activity. Both ADCs are set to enter first-in-human phase 1 studies in 2022.

Stock Upgrades: Seagen Inc Shows Rising Relative Strength
05 Nov, 2021 FinancialContent

A Relative Strength Rating upgrade for Seagen Inc shows improving technical performance. Will it continue?

Notable Seagen Insider Trades $7.4M In Company Stock
04 Nov, 2021 FinancialContent

Jean I Liu, Gc/EVP And Leg Afairs at Seagen (NASDAQ:SGEN), made a large buy and sell of company shares on November 1, according to a ...

Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting
04 Nov, 2021 FinancialContent

Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at Upcoming 2021 American Society of Hematology Annual Meeting

CNBC's Final Trades: Seagen, Dollar Tree And This Pharma Major
04 Nov, 2021 FinancialContent

On CNBC’s “Halftime Report Final Trades,” Brenda Vingiello of Sand Hill Global Advisors said there ...

3 Biotech Stocks That Could Make You Richer
30 Oct, 2021 FinancialContent

The best may be yet to come for these companies.

Expert Ratings For Seagen
29 Oct, 2021 FinancialContent

Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
29 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study ...

Seattle Genetics (SGEN) Q3 2021 Earnings Call Transcript
29 Oct, 2021 FinancialContent

SGEN earnings call for the period ending September 30, 2021.

Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates
28 Oct, 2021 Yahoo! Finance

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -187.50% and 9.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Seagen Reports Third Quarter 2021 Financial Results
28 Oct, 2021 FinancialContent

Seagen Inc. (Nasdaq:SGEN) reported financial results today for the third quarter and nine months ended September 30, 2021. The Company also highlighted ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib) and TIVDAK™ (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its robust oncology pipeline.

Earnings Scheduled For October 28, 2021
28 Oct, 2021 FinancialContent

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per ...

Seattle Genetics's Earnings Outlook
27 Oct, 2021 FinancialContent

Seattle Genetics (NASDAQ:SGEN) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need ...

10 Biggest Price Target Changes For Wednesday
27 Oct, 2021 FinancialContent

Raymond James raised Alphabet Inc. (NASDAQ: GOOGL) price target from $3,200 to $3,400. Alphabet shares fell 0.7% to $2,767.04 in ...

2 Stocks That Have Doubled the S&P 500's Returns Over the Past 5 Years and Could Still Go Higher
22 Oct, 2021 FinancialContent

These companies just keep on growing.

Earnings Preview: Seattle Genetics (SGEN) Q3 Earnings Expected to Decline
21 Oct, 2021 Yahoo! Finance

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 Penny Stocks to Buy to Sidestep the Noise on Wall Street
21 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With so much chaos occurring on Wall Street, these lesser-known penny stocks to buy might fly profitably under the radar. The post 7 Penny Stocks to Buy to Sidestep the Noise on Wall Street appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

3 Stocks to Watch Closely This Earnings Season
21 Oct, 2021 FinancialContent

One Motley Fool contributor is looking forward to the quarterly updates from these healthcare stocks.

Is Seagen Inc.'s(NASDAQ:SGEN) Recent Stock Performance Tethered To Its Strong Fundamentals?
19 Oct, 2021 Yahoo! Finance

Seagen's (NASDAQ:SGEN) stock is up by a considerable 18% over the past three months. Since the market usually pay for a...

Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings
15 Oct, 2021 FinancialContent

Stock futures were pointing to a higher open even beforeGoldman Sachs(NYSE: GS) reported better than expected earnings. ...

2 Penny Stocks That Could Soar Soon
14 Oct, 2021 FinancialContent

These two tiny drugmakers might be hidden gems.

3 Biotech Stocks You Can Buy and Hold for the Next Decade
13 Oct, 2021 FinancialContent

Balance risk and reward with these proven drugmakers.

Is Seagen Inc. (SGEN) A Good Stock To Buy?
12 Oct, 2021 Yahoo! Finance

With the second-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the third quarter of 2021. One of these stocks was Seagen Inc. (NASDAQ:SGEN). Is SGEN a good stock […]

Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
12 Oct, 2021 FinancialContent

Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that patient enrollment was completed in Cohort K of the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869). The cohort is evaluating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. Merck is known as MSD outside the United States and Canada.

Seagen Inc (SGEN) is a NASDAQ Common Stock listed in , ,

970x250